 1. Patients with advanced leukemia or other hematologic malignancy including AML, ALL, CML, and MDS. Advanced features include: a Induction failure, prolonged induction beyond 6 weeks b Incomplete response to salvage therapy c CML in blast crisis or acute leukemia in chemotherapy resistant relapse d secondary leukemia or secondary myelodysplastic disease 